JAK2 JH2 Domain (V617F, W659A, W777A, F794H mutant; human, recombinant; aa 536-812)

Formulation: 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride, 0.5 mM TCEP, and 20% glycerol

Purity: ≥90% estimated by SDS-PAGE

Formula Weight: 0

Shelf life (days): 180

Notes: JAK2 is a non-receptor tyrosine kinase that has roles in immune signaling.{19346,54923} It is composed of N-terminal FERM and SH2 domains, a regulatory JH2 pseudokinase domain, and a C-terminal JH1 kinase domain. It is widely expressed and associates with class I and class II cytokine receptors at the plasma membrane.{54921,54922} Activation of these cytokine receptors activates JAK2 and induces its dimerization and kinase activity, leading to JAK2 phosphorylation of STAT transcription factors and transcription of immune-related target genes. JAK2 signaling is inhibited by the suppressor of cytokine signaling (SOCS) proteins SOCS1 and SOCS3.{54924,54925} Mutagenesis of the JAK2 JH2 domain to contain W659A, W777A, and F794H mutations and truncation at Asp812 increases the solubility of recombinant wild-type JAK2 and JAK2V617F.{51919} Gain-of-function mutations in JAK2, such as JAK2V617F in the JH2 domain, are associated with various blood disorders, including leukemias and myeloproliferative neoplasms.{54922} Cayman’s JAK2 JH2 Domain (V617F, W659A, W777A, F794H mutant; human, recombinant; aa 536-812) protein can be used for binding assays and has a calculated molecular weight of 33 kDa.

• Artikelnummer: CAY42274-20
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 42274-20
• Verpackungseinheit: 20 µg
• Mengeneinheit: STK
• Klonalität: Recombinant